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The important role of combined chemoradiation for several groups of patients with non-
small cell lung cancer (NSCLC) is reflected by the large number of scientific articles
published during the last 30 years. Different measures of impact and clinical relevance of
published research are available, each with its own pros and cons. For this review, article
citation rate was chosen. Highly cited articles were identified through systematic search
of the citation database Scopus. Among the 100 most often cited articles, meta-analyses
(n=5) achieved a median of 203 citations, guidelines (n=7) 97, phase III trials (n=29) 168,
phase II trials (n=21) 135, phase I trials (n=7) 88, and others combined 115.5 (p=0.001).
Numerous national and international cooperative groups and several single institutions
were actively involved in performing often cited, high-impact trials, reflecting the fact that
NSCLC is a world-wide challenge that requires research collaboration. Platinum-containing
combinations have evolved into a standard of care, typically administered concurrently.The
issue of radiotherapy fractionation and total dose has also been studied extensively, yet
with less conclusive results. Differences in target volume definition have been addressed.
However, it was not possible to test all theoretically possible combinations of radiotherapy
regimens, drugs, and drug doses (lower radiosensitizing doses compared to higher sys-
temically active doses).That is why current guidelines offer physicians a choice of different,
presumably equivalent treatment alternatives. This review identifies open questions and
strategies for further research.
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BACKGROUND
Combined radio- and chemotherapy has since the 1980s evolved
into a standard of care for a considerable proportion of patients
with stage III non-small cell lung cancer (NSCLC) (1–3). Impor-
tantly, stage III describes a heterogeneous population with dis-
ease presentation ranging from apparently resectable tumors with
occult microscopic nodal metastases to unresectable, large vol-
ume nodal disease. Even discriminating between stage IIIA and B
does not fully resolve this problem. One of the most controver-
sial issues in patients potentially accessible for surgery is the role
of neoadjuvant therapy (4). As recently summarized, neoadjuvant
therapy followed by surgery is neither clearly better nor clearly
worse than definitive chemoradiation (5). Most of the arguments
made regarding patient selection for neoadjuvant therapy and sur-
gical resection provide evidence for better prognosis but not for
a beneficial impact of this treatment strategy. We will not discuss
in greater detail the emerging role of image-guided stereotactic
radiotherapy as boost or salvage treatment (6, 7) because most
data on this modality were derived from studies of stage I NSCLC,
where ongoing randomized trials compare surgery to stereotactic
radiotherapy (8–11). Both individual institutions and coopera-
tive groups successfully completed an impressive series of clinical
trials for advanced NSCLC, many of whom resulted in practice-
changing insights. For several reasons including but not limited to
tenure track or likelihood of future funding, researchers attempt
to publish their results in a way that ensures high visibility and
allows for broad adoption of the progress achieved. Landmark
studies often appear in prestigious high-impact journals, and are
likely to be cited in editorials, reviews, guidelines, etc., (12). Num-
ber of acquired citations might be a measure that can be used
when performing systematic reviews because it eliminates subjec-
tive preferences when selecting influential research to be included
(13). For the present review, we relied on citation-based selection
of studies, and secondary we hypothesized that randomized clin-
ical trials and meta-analyses acquired more citations than other
types of research.
MATERIALS AND METHODS
A systematic search of the citation database Scopus (Elsevier B.V.,
www.scopus.com) by use of the term “radiotherapy and lung can-
cer” was performed on 16th March 2013. Articles were selected
irrespective of language, year of publication, and article type
(review, guideline, clinical study, experimental study, etc.). In order
to determine whether or not a given article reported on NSCLC
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and combined radio- and chemotherapy we accessed its abstract
if the title was not sufficiently informative. Then, all articles deal-
ing with the subject of this review were ranked by number of
citations (field “times cited” in the Scopus citation database) in
order to create a list (top 100) of articles with the highest num-
ber of citations. The top 100 articles were reviewed for contents
incl. study type (phase I, II, III, retrospective, etc.) and outcomes.
Moreover, the following parameters were evaluated: journal in
which an article was published, number of authors, and type of
research. A complete list of top 100 articles can be requested from
the corresponding author.
RESULTS
The 100 most often cited articles were published between 1984 and
2010 (Figure 1, only three articles were published before 1991).
They achieved a median number of 124 citations (range 66–2733).
Articles published before 2000 achieved a median of 137 citations
(range 66–2733). Those published in the time period 2000–2010
achieved a median of 100 citations (range 66–985). In order to
cover the most recent results and trends, we also extracted the
top 10 publications from the year 2011 (14–23). They achieved a
median of 14.5 citations (range 12–34). References (24–48) rep-
resent the 25 most cited articles overall. With regard to the top
100 publications, 3 were written by more than 20 authors. Eight
had 15–20 authors, 36 had 10–14 authors, the majority (41) had
5–9 authors, and 12 had less than 5 authors (median number
9, range 1–35). Twenty-nine articles reported on phase III clini-
cal trials (phase II: 21, phase I: 7), five were meta-analyses, seven
guidelines, and two literature reviews. The remaining were retro-
spective and preclinical studies. Meta-analyses achieved a median
of 203 citations, guidelines 97, phase III trials 168, phase II tri-
als 135, phase I trials 88, and others combined 115.5 (p= 0.001,
chi square test). Most articles were published in the Journal of
Clinical Oncology (n= 43), the International Journal of Radia-
tion Oncology Biology and Physics (n= 15), the Journal of the
National Cancer Institute and the Journal of Thoracic and Car-
diovascular Surgery (n= 5 each), Clinical Cancer Research and
Annals of Thoracic Surgery (n= 4 each), as well as Chest (n= 3).
Five publications on major randomized clinical studies emanated
from US or US and Canadian intergroup trials, six from SWOG tri-
als, five from CALGB trials, and four from RTOG trials. Between
one and three publications were related to trials performed by
ECOG,EORTC,Hoosier Oncology Group,California Cancer Con-
sortium, and different other groups from Australia, China, Europe,
and Japan. Cooperative group studies accumulated a median of
154 citations compared to 107 citations for studies not performed
by cooperative groups (p= 0.02).
DISCUSSION
The objective of this review was to identify influential, highly cited
scientific publications and thereby research mainstreams related
to chemoradiation treatment for NSCLC. After arbitrary decisions
about which database to search and which keywords to use, we per-
formed a systematic literature search. Citation rate of published
articles was evaluated. Articles with high numbers of citations are
likely those that impressed other clinicians/scientists and had pro-
found influence on clinical practice or future developments in the
FIGURE 1 | Number of articles published per year.
field. It should be noticed that searches in different databases will
result in more or less variable citation counts and that the present
results therefore provide only a snapshot. Our results are consis-
tent with the assumption that citation rate is gradually increasing
for several years after publication. However, the purpose of this
overview was not to explore dynamics of citation count. Meta-
analyses and phase III trials were the publications accumulating
the highest numbers of citations, a finding already described for
other types of cancer (13). However, we focused on top 100 articles
rather than all meta-analyses and clinical trials on chemoradiation.
All major international cooperative groups were actively involved
in often cited, high-impact trials, reflecting the fact that NSCLC is
a world-wide challenge requiring research collaboration. Cooper-
ative group trials achieved a significantly higher median number
of citations compared to other trials. Given the complexity of large
clinical trials, which often include companion biomarker studies,
and require rapid patient accrual, cooperative groups with their
dedicated infrastructure might have advantages in conducting
these important studies with potentially practice-changing impli-
cations. Typically, convincing phase III data are required before
new therapeutic approaches are adopted in the oncology commu-
nity. However, exceptions from this rule are possible, for example
the rapid and widespread use of stereotactic radiotherapy for stage
I NSCLC or approval of crizotinib in patients with rearrangements
of anaplastic lymphoma kinase (ALK) gene.
The interest in combined modality treatment is old and caused
by the fact that neither treatment modality by itself provided sat-
isfactory clinical outcomes. Studies performed in the 1980s often
examined non-concomitant approaches [induction chemother-
apy followed by radiation (28) or pre and post irradiation
chemotherapy (49)]. However, initial concomitant approaches
also date back to this time period (27, 50). Platinum-containing
combinations have evolved into a standard of care (26, 27, 35),
typically administered concurrently (14, 24, 51). The issue of
radiotherapy fractionation has also been studied extensively (con-
ventional daily 1.8–2 Gy fractions to approximately 60–66 Gy,
hyperfractionation, acceleration by more than one daily fraction,
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acceleration by hypofractionation) (23, 34, 39). So far, conven-
tional fractionation continues to be equivalent to altered frac-
tionation. Overall treatment time increases when attempting dose
escalation with conventional fractionation, and this factor might
limit the efficacy of numerically more intense radiotherapy reg-
imens (18). One possibility to reduce overall treatment time is
the use of hypofractionation, either during the whole course
of chemoradiation or for example by use of stereotactic boost
radiotherapy (52, 53), thereby administering a high biologically
effective dose within a standard time frame. The same problem of
accelerated repopulation of cancer cells during prolonged treat-
ment could explain the lack of benefit from sequential chemo-
and radiotherapy as compared to concurrent administration (51).
Stereotactic radiotherapy is now also being studied for patients
with locally recurrent disease (54). Differences in target volume
definition have been addressed [avoiding elective lymph node
regions (55), integrating positron emission tomography (PET)
information (22)]. However, it was not possible to test all theo-
retically possible combinations of radiotherapy regimens, drugs,
and drug doses (lower radiosensitizing doses compared to higher
systemically active doses). That is why current guidelines offer
physicians a choice of different, presumably equivalent treatment
alternatives (56), which we will not discuss and repeat in detail.
Introduction of more sophisticated staging incl. PET, refine-
ment of TNM categories, and increasing frequency of non-
squamous cell carcinoma histologies make it difficult to compare
contemporary and historic patient groups. The prognostic and
predictive impact of primary and total tumor volume, number
of involved lymph nodes, and pattern of lymphatic spread incl.
number of involved stations needs to be determined in a more
rigorous fashion (57). Moreover, NSCLC is a biologically hetero-
geneous group of diseases. Even if molecular categories continue
to evolve, therapeutic implications are already evident (use of
pemetrexed or epidermal growth factor receptor inhibitors, and
more targeted agents are currently being tested). As seen with
bevacizumab (58), toxicity of full dose platinum-based chemora-
diation plus additional agents might be prohibitive, depending
on pathways targeted by new agents. The picture gets even more
complicated when one adds host heterogeneity (age, comorbid-
ity, nutrition status). Clearly, not all patients are suitable for the
most efficacious concurrent regimens (59). In such cases, sequen-
tial treatment still might be considered, as is the case when initial
tumor volume would necessitate prohibitively high normal lung
dose.
At present, many open questions remain. Does addition of
surgery to chemoradiation [an intensely studied paradigm (29,
36, 41, 43, 46)] provide better outcomes, and if so in patients
with primarily resectable stage III disease and those with more
advanced disease but favorable response to induction? Or is this
approach relevant only for superior sulcus tumors (60)? Is radi-
ation dose escalation still promising or a futile approach that
only increases toxicity (18)? Esophagitis and pneumonitis are
well known dose-limiting toxicities (61–64). Can proton therapy
overcome limitations of other techniques (19, 21)? Will pharma-
cological toxicity mitigation strategies ever make it into routine
clinical practice (65)? Will innovative concepts of consolidation
chemotherapy after chemoradiation perform better than previ-
ous attempts (37, 66, 67)? Is there a role for PET not only prior
to treatment but also during chemoradiation, predicting efficacy,
or allowing for treatment plan adaptation (17)? Can we iden-
tify those elderly patients who will tolerate intense combined
modality treatment (68)? Both local failure resulting from sur-
viving tumor stem cells and development of distant metastases
contribute to the modest long-term survival after chemoradi-
ation (69). Some of the studies reviewed here attempted to
improve only one, others both sources of failure. Development
of brain metastases is a threat to many patients with initial
stage III disease. So far, prophylactic cranial radiotherapy has
not improved overall survival (70, 71). Despite these challenges,
progress has been achieved and much has been learned. Tech-
nological, molecular, and pharmacological progress provides a
basis for new generations of clinical trials. Continued support
by patients, health care providers, payors, and sponsors is nec-
essary to pursue the bumpy yet successful way toward survival
improvement.
CONCLUSION
Citation count might aid individuals who try to identify important
studies to achieve this goal. Progress in chemoradiation develop-
ment was largely driven by cooperative groups and some dedicated
single institutions, which pursued their concepts through differ-
ent stages of clinical trials, often culminating in successful phase
III trials. The latter as well as meta-analyses are likely to change
clinical practice and achieve high citation counts.
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